CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges
- 5 February 2019
- book chapter
- Published by Springer Nature
- Vol. 1144, 37-52
Abstract
Sickle cell disease (SCD) is an inherited monogenic disorder resulting in serious mortality and morbidity worldwide. Although the disease was characterized more than a century ago, there are only two FDA approved medications to lessen disease severity, and a definitive cure available to all patients with SCD is lacking. Rapid and substantial progress in genome editing approaches have proven valuable as a curative option given plausibility to either correct the underlying mutation in patient-derived hematopoietic stem/progenitor cells (HSPCs), induce fetal hemoglobin expression to circumvent sickling of red blood cells (RBCs), or create corrected induced pluripotent stem cells (iPSCs) among other approaches. Recent discovery of CRISPR/Cas9 has not only revolutionized genome engineering but has also brought the possibility of translating these concepts into a clinically meaningful reality. Here we summarize genome engineering applications using CRISPR/Cas9, addressing challenges and future perspectives of CRISPR/Cas9 as a curative option for SCD.Keywords
This publication has 102 references indexed in Scilit:
- High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificityNature Biotechnology, 2013
- Global Burden of Sickle Cell Anaemia in Children under Five, 2010–2050: Modelling Based on Demographics, Excess Mortality, and InterventionsPLOS Medicine, 2013
- High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cellsNature Biotechnology, 2013
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- RNA-guided genetic silencing systems in bacteria and archaeaNature, 2012
- Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)The Lancet, 2011
- Homing Endonucleases: From Microbial Genetic Invaders to Reagents for Targeted DNA ModificationStructure, 2011
- Genome editing with engineered zinc finger nucleasesNature Reviews Genetics, 2010
- The cost of health care for patients with sickle cell diseaseAmerican Journal of Hematology, 2009
- Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemiaProceedings of the National Academy of Sciences, 2008